Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.66 |
| ▸ | BRD2 | P25440 | 2/20 | 0.66 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.55 |
| ▸ | MLYCD | O95822 | 1/20 | 0.54 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8300240 | 0.83 | BRD4 (0.70) | BRD4BRD2BRD3MLYCDCREBBP | |
| SCHEMBL9932071 | 0.82 | BRD4 (0.57) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL17532582 | 0.81 | BRD4 (0.68) | BRD4BRD2 | |
| SCHEMBL14196935 | 0.81 | BRD4 (0.61) | BRD4BRD2BRD3MLYCDCREBBP | |
| SCHEMBL12362813 | 0.80 | BRD4 (0.66) | BRD4BRD2MLYCDCREBBP | |
| SCHEMBL3885694 | 0.80 | BRD4 (0.66) | BRD4BRD2BRD3MLYCDCREBBP | |
| SCHEMBL16404607 | 0.80 | BRD4 (0.66) | BRD4BRD2MLYCDLMNACYP3A4 | |
| SCHEMBL1772573 | 0.80 | BRD4 (0.66) | BRD4BRD2BRD3MLYCDCREBBP | |
| 3,5-Dimethyl-4-Phenylisoxazole SCHEMBL12134072 | 0.79 | BRD4 (1.00) | BRD4BRD2MLYCDCREBBP | |
| SCHEMBL16540910 | 0.79 | HEXA (0.49) | BRD4BRD2HSD11B1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256740-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2747560-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013085890-A1 | THERAPEUTIC METHODS | GLAXO GROUP LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013019635-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256740-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | BRD4 524/4885BRD2 1146/4885BRD3 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.